HK1217643A1 - 抗體藥物偶聯物 純化 - Google Patents
抗體藥物偶聯物 純化Info
- Publication number
- HK1217643A1 HK1217643A1 HK16105608.5A HK16105608A HK1217643A1 HK 1217643 A1 HK1217643 A1 HK 1217643A1 HK 16105608 A HK16105608 A HK 16105608A HK 1217643 A1 HK1217643 A1 HK 1217643A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- adc
- purification
- drug conjugate
- antibody drug
- antibody
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792834P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027062 WO2014152199A1 (en) | 2013-03-15 | 2014-03-14 | Antibody drug conjugate (adc) purification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1217643A1 true HK1217643A1 (zh) | 2017-01-20 |
Family
ID=50686153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16105608.5A HK1217643A1 (zh) | 2013-03-15 | 2016-05-16 | 抗體藥物偶聯物 純化 |
| HK16107159.4A HK1219056A1 (zh) | 2013-03-15 | 2016-06-21 | 抗體藥物偶聯物 純化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16107159.4A HK1219056A1 (zh) | 2013-03-15 | 2016-06-21 | 抗體藥物偶聯物 純化 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20140286968A1 (zh) |
| EP (2) | EP2968589A1 (zh) |
| JP (1) | JP2016519070A (zh) |
| KR (1) | KR20150132864A (zh) |
| CN (1) | CN105209076A (zh) |
| AU (1) | AU2014240012A1 (zh) |
| BR (1) | BR112015023520A2 (zh) |
| CA (1) | CA2906022A1 (zh) |
| HK (2) | HK1217643A1 (zh) |
| IL (1) | IL241004A0 (zh) |
| MX (1) | MX2015012562A (zh) |
| NZ (1) | NZ630888A (zh) |
| RU (1) | RU2015144186A (zh) |
| SG (2) | SG11201507432XA (zh) |
| TW (1) | TW201519904A (zh) |
| WO (1) | WO2014152199A1 (zh) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| TWI689313B (zh) * | 2013-03-15 | 2020-04-01 | 德商艾伯維德國有限及兩合公司 | 抗-ｅｇｆｒ抗體藥物結合物調配物 |
| TWI684600B (zh) | 2014-03-21 | 2020-02-11 | 美商艾伯維有限公司 | 抗－ｅｇｆｒ抗體及抗體藥物結合物 |
| US10792370B2 (en) | 2015-02-17 | 2020-10-06 | Shanghai Miracogen Inc | Antibody-drug conjugate |
| WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
| SG10201913762QA (en) | 2015-05-04 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
| US20190153107A1 (en) | 2016-06-08 | 2019-05-23 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
| CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| EP3468616A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
| LT3458479T (lt) | 2016-06-08 | 2021-02-25 | Abbvie Inc. | Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai |
| BR112018075649A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo |
| KR102369014B1 (ko) * | 2016-08-16 | 2022-03-02 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
| TWI631958B (zh) * | 2016-11-02 | 2018-08-11 | 財團法人生物技術開發中心 | 抗tmcc3免疫共軛物及其用途 |
| CA3048224A1 (en) * | 2016-12-23 | 2018-06-28 | Bluefin Biomedicine, Inc. | Anti-sez6l2 antibodies and antibody drug conjugates |
| CN107375941A (zh) * | 2017-07-17 | 2017-11-24 | 中国药科大学 | 一种抗人dll4单克隆抗体与海兔毒素衍生物mmae的偶联物 |
| WO2019173911A1 (en) | 2018-03-13 | 2019-09-19 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| CN114025805A (zh) * | 2019-06-07 | 2022-02-08 | 达因疗法公司 | 制备蛋白质-寡核苷酸复合物的方法 |
| CA3146471A1 (en) | 2019-08-06 | 2021-02-11 | James K. Kranz | Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders |
| CN112604004B (zh) * | 2019-09-19 | 2022-05-10 | 中国医学科学院医药生物技术研究所 | 一类抗人egfr抗体药物偶联物及其制备方法与应用 |
| CA3081503A1 (en) | 2019-12-06 | 2021-06-06 | Zymeworks Inc. | Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2023012669A2 (en) | 2021-08-03 | 2023-02-09 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and stable isotope labeling peptide mapping method |
| EP4429654A1 (en) | 2021-11-09 | 2024-09-18 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| CN118290513A (zh) * | 2024-06-05 | 2024-07-05 | 东曜药业有限公司 | 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| ES2313867T3 (es) | 1991-12-02 | 2009-03-16 | Medical Research Council | Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| JP2004532611A (ja) * | 2000-11-28 | 2004-10-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１９ |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| JP4861308B2 (ja) * | 2004-04-07 | 2012-01-25 | ジェネンテック， インコーポレイテッド | 抗体結合体の質量分析 |
| US8039273B2 (en) | 2005-07-18 | 2011-10-18 | Seattle Genetics, Inc. | β-glucuronide-linker drug conjugates |
| US8158590B2 (en) | 2005-08-05 | 2012-04-17 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation |
| RU2011148913A (ru) * | 2009-05-01 | 2013-06-10 | Эбботт Лэборетриз | Иммуноглобулин с двумя вариабельными доменами и его применение |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| SG11201406943XA (en) * | 2012-04-27 | 2014-12-30 | Cytomx Therapeutics Inc | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
-
2014
- 2014-03-14 BR BR112015023520A patent/BR112015023520A2/pt not_active IP Right Cessation
- 2014-03-14 NZ NZ630888A patent/NZ630888A/en not_active IP Right Cessation
- 2014-03-14 RU RU2015144186A patent/RU2015144186A/ru not_active Application Discontinuation
- 2014-03-14 AU AU2014240012A patent/AU2014240012A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027062 patent/WO2014152199A1/en active Application Filing
- 2014-03-14 KR KR1020157029906A patent/KR20150132864A/ko not_active Application Discontinuation
- 2014-03-14 MX MX2015012562A patent/MX2015012562A/es unknown
- 2014-03-14 SG SG11201507432XA patent/SG11201507432XA/en unknown
- 2014-03-14 CN CN201480025357.3A patent/CN105209076A/zh active Pending
- 2014-03-14 EP EP14722865.4A patent/EP2968589A1/en not_active Withdrawn
- 2014-03-14 JP JP2016502325A patent/JP2016519070A/ja active Pending
- 2014-03-14 SG SG10201800313UA patent/SG10201800313UA/en unknown
- 2014-03-14 CA CA2906022A patent/CA2906022A1/en not_active Abandoned
- 2014-03-14 TW TW103109819A patent/TW201519904A/zh unknown
- 2014-03-14 EP EP22179414.2A patent/EP4137160A1/en not_active Withdrawn
- 2014-03-14 US US14/210,602 patent/US20140286968A1/en not_active Abandoned
-
2015
- 2015-09-01 IL IL241004A patent/IL241004A0/en unknown
-
2016
- 2016-05-16 HK HK16105608.5A patent/HK1217643A1/zh unknown
- 2016-06-21 HK HK16107159.4A patent/HK1219056A1/zh unknown
-
2019
- 2019-02-11 US US16/273,034 patent/US20190262417A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4137160A1 (en) | 2023-02-22 |
| WO2014152199A1 (en) | 2014-09-25 |
| KR20150132864A (ko) | 2015-11-26 |
| BR112015023520A2 (pt) | 2017-10-24 |
| EP2968589A1 (en) | 2016-01-20 |
| RU2015144186A3 (zh) | 2018-03-19 |
| HK1219056A1 (zh) | 2017-03-24 |
| IL241004A0 (en) | 2015-11-30 |
| TW201519904A (zh) | 2015-06-01 |
| NZ630888A (en) | 2017-06-30 |
| US20140286968A1 (en) | 2014-09-25 |
| RU2015144186A (ru) | 2017-04-24 |
| US20190262417A1 (en) | 2019-08-29 |
| JP2016519070A (ja) | 2016-06-30 |
| SG11201507432XA (en) | 2015-10-29 |
| CA2906022A1 (en) | 2014-09-25 |
| MX2015012562A (es) | 2016-06-21 |
| CN105209076A (zh) | 2015-12-30 |
| SG10201800313UA (en) | 2018-02-27 |
| AU2014240012A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1219056A1 (zh) | 抗體藥物偶聯物 純化 | |
| ZA201905426B (en) | Drug combinations | |
| HK1210477A1 (zh) | 抗體-藥物偶聯物 | |
| IL241277A0 (en) | Antibody-drug conjugates | |
| GB2529950B (en) | Patient support | |
| GB2532671B (en) | Patient support | |
| ZA201508487B (en) | Antibody drug conjugates | |
| EP3060578A4 (en) | Antibody purification | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| SG11201600666SA (en) | Medicament comprising anti-phospholipase d4 antibody | |
| ZA201506465B (en) | Pharmaceutical preparation | |
| GB201310496D0 (en) | Pharmaceutical combinations | |
| GB201301723D0 (en) | Pharmaceutical combinations |